Ranked #7,608 of 8,699 institutional investors
Kalehua Capital Management LLC
Dallas, TX
$123M
US stock portfolio at live prices · today −$236K (−0.19%)
Live prices, last trade 12:41 PM ET
- Value at quarter end (Q3 2026)
- $132M
- Change from Q2 2026
- −$181.1M (−57.77%)
- Positions
- 18 · 6 new, 8 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: none$10.7M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesBOXX 14.3%MANE 14.2%KRSA 13.4%XFOR 9.08%SRZN 6.73%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| BOXX Alpha Architect 1-3 Month Box ETF | 148,471 | $17.7M | 14.3% | Reduced −34% |
| MANE Veradermics Inc | 145,695 | $17.5M | 14.2% | Reduced −50% |
| KRSA Korsana Biosciences, Inc. | 442,653 | $16.6M | 13.4% | New |
| XFOR X4 Pharmaceuticals, Inc. | 3,722,840 | $11.2M | 9.08% | Reduced −50% |
| SRZN Surrozen, Inc. | 286,092 | $8.3M | 6.73% | Reduced −63% |
| SEPN Septerna, Inc. | 194,544 | $7.6M | 6.15% | Reduced −50% |
| ACRS Aclaris Therapeutics, Inc. | 1,832,365 | $6.3M | 5.13% | Reduced −50% |
| KRRO Korro Bio, Inc. | 473,595 | $5.9M | 4.76% | Added +17% |
| IKT Inhibikase Therapeutics, Inc. | 3,821,890 | $5.2M | 4.21% | Reduced −50% |
| OBX Obsidian Therapeutics, Inc. | 416,649 | $5.0M | 4.02% | New |
| BETRF BetterLife Pharma Inc. | 27,710,000 | $3.8M | 3.10% | New |
| ATTO Attovia Therapeutics, Inc. | 200,000 | $3.0M | 2.46% | New |
| GOSS Gossamer Bio, Inc. | 139,366 | $1.6M | 1.27% | Reduced −50% |
| LONA LeonaBio, Inc. | 393,701 | $911K | 0.74% | Reduced −50% |
| RNA Atrium Therapeutics, Inc. | 112,652 | $799K | 0.65% | New |
| MIST Milestone Pharmaceuticals Inc. | 1,651,258 | $619K | 0.50% | Reduced −35% |
| TIL Instil Bio, Inc. | 99,600 | $533K | 0.43% | Reduced −50% |
| KZIA Kazia Therapeutics Limited | 56,013 | $264K | 0.21% | New |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| CMPS COMPASS Pathways plc | 1,639,384 | $13.3M |
| MLTX MoonLake Immunotherapeutics | 351,468 | $3.9M |
| NVCT Nuvectis Pharma, Inc. | 200,000 | $3.8M |
| TYRA Tyra Biosciences, Inc. | 148,930 | $3.0M |
| ANL Adlai Nortye Group Ltd. | 226,415 | $2.0M |
| SION Sionna Therapeutics, Inc. | 394,144 | $1.1M |
| TCRX TScan Therapeutics, Inc. | 909,752 | $137K |
| KPTIQ Karyopharm Therapeutics Inc. | 1,371,288 | $45K |